Miwa Toru, Kita Tomoko, Yamaguchi Taro, Sakamoto Tatsunori
Otolaryngology, Osaka Metropolitan University, Osaka, JPN.
Otolaryngology-Head and Neck Surgery, Kyoto University, Kyoto, JPN.
Cureus. 2022 Oct 17;14(10):e30406. doi: 10.7759/cureus.30406. eCollection 2022 Oct.
Introduction and objectives Acquired sensorineural hearing loss (SNHL) has become a critical societal issue in recent years. SNHL is considered a risk factor for type 2 diabetes mellitus (T2DM). Metformin is commonly used to treat T2DM. However, its effects on SNHL have not been reported yet. Hence, this study aimed to evaluate the association between the use of metformin and SNHL incidence. Patients and methods In this retrospective matched-cohort study, the medical records of 1219 patients with T2DM aged >18 years from our hospital's inpatient database from January 1, 2012, to December 31, 2019, were examined, and matched cohorts were generated (76 patients receiving metformin and 76 not receiving metformin). A multivariable logistic regression analysis was performed to investigate the factors influencing the incidence of SNHL. Results After adjustment by propensity matching, multivariable logistic regression analysis revealed that the non-use of metformin increased the risk of developing SNHL (odds ratio, 0.26; 95% confidence interval, 0.07-0.93; p = 0.03). Conclusions This study demonstrated an association between the use of metformin and a reduced incidence of SNHL among patients with T2DM.
引言与目的 近年来，获得性感音神经性听力损失（SNHL）已成为一个关键的社会问题。SNHL被认为是2型糖尿病（T2DM）的一个风险因素。二甲双胍常用于治疗T2DM。然而，其对SNHL的影响尚未见报道。因此，本研究旨在评估二甲双胍的使用与SNHL发病率之间的关联。 患者与方法 在这项回顾性匹配队列研究中，检查了我院2012年1月1日至2019年12月31日住院数据库中1219例年龄>18岁的T2DM患者的病历，并生成匹配队列（76例接受二甲双胍治疗和76例未接受二甲双胍治疗）。进行多变量逻辑回归分析以研究影响SNHL发病率的因素。 结果 通过倾向匹配调整后，多变量逻辑回归分析显示，未使用二甲双胍会增加发生SNHL的风险（比值比，0.26；95%置信区间，0.07 - 0.93；p = 0.03）。 结论 本研究证明了二甲双胍的使用与T2DM患者中SNHL发病率降低之间存在关联。
